01:23 PM EDT, 10/22/2024 (MT Newswires) -- ENDRA Life Sciences ( NDRA ) shares more than doubled Tuesday after the company said a post market clinical study was started at the LMU University Hospital in Munich, Germany to assess the liver fat measurement capabilities of its TAEUS system.

The company said a first patient was scanned with the TAEUS system in the study, which is designed to assess the system's utility for managing metabolic disease.

ENDRA said it expects the collaboration with LMU researchers to augment clinical data and support the company's de novo submission to the US Food and Drug Administration by mid-2025.

Price: 0.49, Change: +0.27, Percent Change: +124.43